ARDX
Ardelyx, Inc.
Biotechnology · Healthcare · United States
3.10
close · 2026-10-29
value
40
cheaper than peers40
quality
43
stronger fundamentals43
ranked against
Biotechnology (commercial)
value
quality
161 peerswide variation
caveat margins at their own peak
Value inputs
| measure | company | vs peers |
| price to sales | 2.81× | 88 |
| forward P/E | 10.67× | 84 |
| earnings yield, 1 year ago | -4.2% | 50 |
| earnings yield, 2 years ago | -7.4% | 50 |
| cash flow yield, 1 year ago | -4.4% | 41 |
| price to book | 5.18× | 35 |
| cash flow yield, latest year | -4.2% | 32 |
| earnings yield, 3 years ago | -10.3% | 32 |
| cash flow yield, 2 years ago | -8.6% | 32 |
| cash flow yield, 3 years ago | -6.7% | 32 |
| earnings yield, latest year | -6.4% | 23 |
11 of 12 measures available
Quality inputs
| measure | company | vs peers |
| operating margin | -34.7% | 65 |
| return on equity | -39.5% | 61 |
| revenue growth | 27.5% | 54 |
| debt to equity | 157.5% | 16 |
4 of 4 measures available
Facts
| market cap | $800M |
| free cash flow | $86,375 |
| employees | 489 |
| first trade | 2014-06-19 |
| next earnings | 2026-11-03 |
| fundamentals updated | 2026-08-06 |
Annual history
| measure | 2025 | 2024 | 2023 | 2022 |
| diluted eps | -0.26 | -0.17 | -0.30 | -0.42 |
| free cash flow | -$44.0M | -$45.8M | -$90.1M | -$70.1M |
| net income | -$61.6M | -$39.1M | -$66.1M | -$67.2M |
| revenue | $407.3M | $333.6M | $124.5M | $52.2M |